Advances in the treatment of macular edema secondary to retinal vein occlusion

Authors: Chu Mengqi,  Shen Lijun

DOI: 10.3760/cma.j.issn.2095-0160.2018.01.014
Published 2018-01-10
Cite as Chin J Exp Ophthalmol, 2018,36(1): 65-69.

Abstract                              [Download PDF] [Read Full Text]

Retinal vein occlusion (RVO) is a common blinding retinal vascular disease, and the most important complication of vision loss is macular edema (ME). The main treatment for ME secondary to RVO was laser photocoagulation therapy previously, but some researches showed that the laser therapy did not see an obvious curative effection, and might cause certain danger in some patients.In recent years, with the further understanding and research of the pathogenesis of RVO, intravitreal injection or posterior subtenon injection of triamcinolone acetonide and anti-vascular endothelial growth factor drugs like ranibizumab, bevacizumab, aflibercept, conbercept intravitreal injections, as well as vitreous retinal surgery gradually became the main research directions of ME secondary to RVO.The following to be a review for the advances in the treatment of macular edema secondary to RVO.

Key words:

Retinal vein occlusion; Macular edema; Treatment; Review

Contributor Information

Chu Mengqi
Eye Hospital of Wenzhou Medical University, Whenzhou 325027, China (now Eye Center of the Second Affiliated Hospital, School of Medicine, Zhejiang University)
Shen Lijun
(Read 151 times, 1 visits today)
Updated: February 15, 2023 — 7:30 am